菜单
Return News
Express | Sanyou Biopharmaceuticals and Dragon Sail Pharmaceutical jointly building a one-stop antibody drug R&D service platform.
Time:2019.03.23 Author:Sanyou Bio From:Sanyou Bio

At the groundbreaking ceremony of Dragon Sail Pharmaceutical - Lin'gang Production Base and the launch conference of NONCROS™ brand held in Lin'gang, held on March 22, Sanyou Biopharmaceuticals and Dragon Sail Pharmaceutical jointly announced their effort in building a one-stop antibody drug R&D service platform.


At this ceremony, held in Shanghai Lin'gang Fengxian Park. Mr. Guojun Lang, Chairman/CEO of Sanyou Biopharmaceuticals, attended and signed the strategic cooperation agreement.


Mr. Xun Zou, Executive Director of Dragon Sail Pharmaceutical, delivered a speech.



At the groundbreaking ceremony and press conference, Mr. Xun Zou, Executive Director of Dragon Sail Pharmaceutical, introduced the construction goal and planning of the industrialization base for production and sales of clinical samples and marketed products of high-end monoclonal antibody drugs of Dragon Sail Pharmaceutical. After completion of the industrialization base, the service scope will cover process development, customized contract production, quality research, registration, declaration, etc. In compliance with the requirements of multi-product co-production in the most efficient and cost-effective manner, and with the maximum production scale up to 12,000 L, the NONCROS™ non-cross antibody production platform will be one of the largest monoclonal antibody production bases in Shanghai.


Mr. Xufei Wang, President of Guilin Sanjin Pharmaceutical, said "Guilin Sanjin Pharmaceutical will offer its full support in terms of capital, management and channels to boost the rapid industrialization development of monoclonal antibody in Dragon Sail Pharmaceutical. 


At the conference, Mr. Guoping Zhao, academician of The Chinese Academy of Sciences, Mr. Shaoxiong Chen, Secretary General of Shanghai Biopharmaceutics Industry Association, Dr. Peizhi Luo, Chairman and President of Tianyan Pharmaceutical, Mr. Rene Faber, Executive Director of Sartorius, Ms. Hongyan Xie, Senior President of GEHC Strategic Customer Relations, and Mr. Johnny Han, General Manager of COCKRAM (China) all conveyed their congratulations and delivered inspiring speeches.



Mr. Guojun Lang, CEO of Sanyou Biopharmaceuticals (left) and Mr. Xun Zou, Executive Director of Dragon Sail Pharmaceutical (right)



At the groundbreaking ceremony, Dragon Sail Pharmaceutical signed respective strategic cooperation agreements with Tianyan Pharmaceutical (Suzhou) Co., Ltd., Shanghai Maiji Biotechnology Co., Ltd. and Sanyou Biopharmaceuticals (Shanghai) Co., Ltd.


Committed to the early R&D service of innovative antibody drugs, Sanyou Biopharmaceutical has strong R&D strength with the completion of its internationally advanced innovative antibody R&D technology platform, which provides high-throughput project incubation and phase technical services for tumors, autoimmune diseases, etc.  Dragon Sail pharmaceutical has a complete process development and production platform of monoclonal antibody drugs, which can be used for large-scale production of monoclonal antibody drugs in accordance with the GMP requirements.


This cooperation with Dragon Sail Pharmaceutical integrates the early R&Dtechnology, platform advantage of Sanyou Biopharmaceuticals with Dragon Sail Pharmaseutical’s rich experience in pharmaceutical process R&D.  This complementary and compatible integration of these two companies will benefit patients around the world with a wider promotion of the R&D process of innovative antibody drugs!

 

About Dragon Sail Pharmaceutical 

Formed in 2016 in Shanghai, Dragon Sail Pharmaceutical (Shanghai) Co., Ltd., is a wholly-owned subsidiary invested by the publicly-traded company Guilin Sanjin Pharmaceutical Co., Ltd.  Attached to Dragon B oat Biopharmaceutical R&D Center established in 2005, Dragon Sail Pharmaceutical has a total investment of RMB 690 million, and is in process of building an industrialization base of R&D, clinical praciton, production and sales of monoclonal antibody drugs against tumors in Fengxian Lin'gang Intelligent Manufacturing Park. With a production scale of 12,000 L and an estimated annual sales of more than RMB 1.0 billion upon completion, Dragon Sail Pharmaceutical will be one of Shanghai's largest monoclonal antibody production bases with   GMP-compliant production capability.